Our Approach

Ardelyx develops:

  • Drugs that target proteins found in the gut whose activities affect the entire body
  • Drugs that are not absorbed, enabling them to achieve systemic efficacy while avoiding systemic toxicity and side effects

What we do

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

What We Do

Targeting Specific Gut Transporters and Receptors

Ardelyx targets specific gut transporters and receptors with drugs that address important medical issues in cardiovascular disease, diabetes and chronic kidney disease.  As research over the last 20 years has yielded an increased understanding of how transporters, receptors and other proteins in the gut affect the rest of the body, Ardelyx has been able to develop drugs that: 

  • Act locally and specifically target those transporters
  • Exhibit restricted absorption across the gastrointestinal (GI) epithelia 
  • Experience minimal gut metabolism.

As a result, these drugs are active against their targets, yet are not absorbed: they survive transit through the gut intact, such that at least 90% is eliminated through the feces.

Ardelyx Drugs are not Limited to Gastrointestinal Diseases
While we use our methods to develop drugs for gastrointestinal disorders such as IBS-C, CIC and OBD, the approach is not limited to GI disease. Indeed, Ardelyx molecules represent a novel means of treating diseases that include mineral metabolism disorders such as chronic kidney disease and hypertension, as well as metabolic diseases such as diabetes. This approach is based on an enhanced understanding of the role the gut plays in the etiology of these diseases.

Gut Transporters and Receptors are Involved in Mineral and Nutrient Metabolism
Imbalance is a prominent feature of mineral metabolism disorders and metabolic diseases. Mineral metabolism disorders are characterized by an imbalance of essential ions such as sodium, phosphate, and potassium; this imbalance largely results from worsening or inadequate kidney function. In the case of metabolic diseases, the imbalance is manifest as a dysregulation of glucose and lipid metabolism.

Ardelyx believes that better drugs can be designed which target such imbalances by working in the gut.  The gut is actively involved in managing the transport of ions and nutrients across the epithelia, while transmitting signals to other systems of the body. The transporters, channels, and receptors located on the GI epithelia play critical roles in the uptake and utilization of nutrients to ensure vital functions. Additionally, these transporters, channels, and receptors keenly sense and transport ions and sugars; they also control the secretion of gut hormones that coordinate the response of the GI tract in processing the contents of a meal into elementary nutrients that are readily absorbed.